Pirodavir is primarily used as an antiviral agent, specifically targeting rhinoviruses, which are the main cause of the common cold. It works by inhibiting viral attachment and entry into host cells, thereby preventing the spread of infection. Due to its mechanism, it has been investigated for use in treating respiratory infections, especially in individuals with compromised immune systems or chronic respiratory conditions. Pirodavir has also shown activity against other picornaviruses, making it a candidate for broad-spectrum antiviral development. Although not widely used clinically, it serves as a valuable research tool in understanding viral replication and host-pathogen interactions.